Moderna Inc (MIL:1MRNA)
€ 38.165 -0.445 (-1.15%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 44/100

Moderna Inc hMPV+PIV3 Interim Data Conference Call Transcript

Feb 12, 2019 / 10:00PM GMT
Operator

Good day, ladies and gentlemen, and welcome to the Moderna hMPV and PIV3 Interim Data Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Ms. Laura Schneck, Investor Relations at Moderna. Ma'am, you may begin.

Laura Schneck
Moderna Therapeutics - IR, Associate Director

Thank you, operator. Good afternoon, everyone, and thank you for joining us today to review the top-line interim clinical data from our Phase 1 study of mRNA-1653, our human metapneumovirus or hMPV and parainfluenza virus type 3 or PIV3 vaccine. You can access the press release for these data and the slides that we'll be reviewing by the going to the Investor section of our website at www.modernatx.com.

With me today are Stephane Bancel, our Chief Executive Officer; and Tal Zaks, our Chief Medical Officer. Lorence Kim, our Chief Financial Officer, is also here and will join us for Q&A

Before

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot